Short answer · Medically reviewed summary · Last updated: 2026-05-08
Recent advances in multiple myeloma treatment have shifted toward immunotherapy, including CAR-T cell therapies and bispecific T-cell engagers, which offer new hope for patients with relapsed or refractory disease. Ongoing research in multiple myeloma focuses on precision medicine and novel drug combinations to improve long-term outcomes and deepen remissions. What are the most promising research directions for multiple myeloma? The current landscape of multiple myeloma research is dominated by immunotherapy.
3 people with Multiple myeloma have shared their first-person experience on this question at DiseaseMaps.
What are the latest advances in Multiple myeloma?
Latest advances in Multiple myeloma: recent research, treatments in development and what they could mean, with sources.
Recent advances in multiple myeloma treatment have shifted toward immunotherapy, including CAR-T cell therapies and bispecific T-cell engagers, which offer new hope for patients with relapsed or refractory disease. Ongoing research in multiple myeloma focuses on precision medicine and novel drug combinations to improve long-term outcomes and deepen remissions.
What are the most promising research directions for multiple myeloma?
The current landscape of multiple myeloma research is dominated by immunotherapy. Researchers are refining chimeric antigen receptor (CAR) T-cell therapies that target BCMA (B-cell maturation antigen), which is highly expressed on multiple myeloma cells. Additionally, the development of bispecific antibodies—which simultaneously bind to cancer cells and immune cells—is transforming the standard of care for patients who have exhausted traditional treatment options.
What recent breakthroughs have been made in treating multiple myeloma?
Recent clinical successes include the FDA approval of several new agents that provide deeper, more durable responses. Key areas of progress include:
- Bispecific T-cell engagers (BiTEs): Therapies like teclistamab have shown high response rates in heavily pre-treated multiple myeloma populations.
- CAR-T Cell Therapy: Innovations in manufacturing and targeting are reducing wait times and improving the safety profile of these potent therapies.
- Combination Regimens: Integrating monoclonal antibodies with proteasome inhibitors and immunomodulatory drugs (IMiDs) has significantly extended progression-free survival.
How can patients participate in clinical trials?
Participation in clinical trials is vital for the development of new multiple myeloma therapies. Patients should consult their hematologist-oncologist to discuss ongoing trials listed on ClinicalTrials.gov. Currently, over 217 community members at DiseaseMaps.org are sharing their experiences, providing a platform to discuss trial access and patient navigation.
Next steps
- Consult a hematologist specializing in plasma cell dyscrasias to discuss the latest therapy options.
- Use ClinicalTrials.gov to search for trials by filtering for "Multiple Myeloma" and your specific geographic location.
- Connect with the Multiple Myeloma Research Foundation (MMRF) for patient support and trial matching services.
- Join the 217 peers at DiseaseMaps.org to share insights and stay updated on community-reported experiences.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Multiple Myeloma
- Multiple Myeloma Research Foundation (MMRF) - Clinical Trial Resources
- National Cancer Institute (NCI) - Multiple Myeloma Treatment Updates
- ClinicalTrials.gov - Registry of active research studies
Posted Jul 19, 2017 by Larry 2100
Posted Jul 19, 2017 by Deb 2000
Panobinostat, the first histone deacetylase inhibitor approved for multiple myeloma, is used in combination with bortezomib and dexamethasone for patients who received 2 prior lines of therapy that included bortezomib and an immunomodulatory agent. “Because it is oral, it is really easy for patients,” Dr Leblebjian noted.
Panobinostat has minimal efficacy as a single agent, but acts synergistically when used in combination. Dosing every alternate week can help patients avoid gastrointestinal and hematologic toxicity, as well as fatigue.
The IgG1κ anti-CD38 antibody daratumumab is approved as fourth-line therapy as a single agent, and as second-line therapy when used in combination with dexamethasone and bortezomib or lenalidomide.
Daratumumab induces apoptosis of CD38-expressing cells, which primarily includes myeloma cells but not normal lymphoid or myeloid cells. Intensive premedication, and early start time, and montelukast can reduce infusion reactions, which most frequently occur during the first or second dose.
Ixazomib is a proteosome inhibitor approved for second-line treatment when used in combination with lenalidomide and dexamethasone. Its advantages compared with other proteosome inhibitors is it is oral with weekly administration. It does not cause peripheral neuropathy, and nausea can be avoided with antiemetic premedication.
The novel anti-SLAMF7 antibody, elotuzumab, is available for second-line treatment in combination with lenalidomide and dexamethasone. Elotuzumab has a dual mechanism whereby it activates natural killer (NK) cells, and promotes the interaction of NK cells with myeloma cells.
RELATED: Myeloma Patients Not Receiving Guideline-recommended Thromboprophylaxis
Elotuzumab has little single-agent efficacy, but “adding the lenalidomide enhances the NK cell activation and increases the antitumor activity,” Dr Leblebjian said. It is well-tolerated with a low incidence of infusion reactions.
Read more of Cancer Therapy Advisor's coverage of the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference by visiting the conference page.
Reference
Leblebjian H. Navigating new treatment paradigms in relapsed or refractory multiple myeloma. Lecture presented at: 13th Hematology/Oncology Pharmacy Association Annual Conference; March 29-April 1, 2017; Anaheim, CA.
Posted Jul 20, 2017 by Tammy Gallet Ward 2000
